These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19151045)

  • 1. Capsaicin receptor antagonists: a promising new addition to the pain clinic.
    Lambert DG
    Br J Anaesth; 2009 Feb; 102(2):153-5. PubMed ID: 19151045
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic antinociceptive effect of a calcium channel blocker and a TRPV1 blocker in an acute pain model in mice.
    Palhares MR; Silva JF; Rezende MJS; Santos DC; Silva-Junior CA; Borges MH; Ferreira J; Gomez MV; Castro-Junior CJ
    Life Sci; 2017 Aug; 182():122-128. PubMed ID: 28629730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1.
    Conway SJ
    Chem Soc Rev; 2008 Aug; 37(8):1530-45. PubMed ID: 18648679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat.
    Varga A; Németh J; Szabó A; McDougall JJ; Zhang C; Elekes K; Pintér E; Szolcsányi J; Helyes Z
    Neurosci Lett; 2005 Sep; 385(2):137-42. PubMed ID: 15950380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
    Westaway SM
    J Med Chem; 2007 May; 50(11):2589-96. PubMed ID: 17489570
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
    Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
    Kanai Y; Hara T; Imai A; Sakakibara A
    J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRPV1 antagonists: clinical setbacks and prospects for future development.
    Kort ME; Kym PR
    Prog Med Chem; 2012; 51():57-70. PubMed ID: 22520471
    [No Abstract]   [Full Text] [Related]  

  • 9. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death.
    Athanasiou A; Smith PA; Vakilpour S; Kumaran NM; Turner AE; Bagiokou D; Layfield R; Ray DE; Westwell AD; Alexander SP; Kendall DA; Lobo DN; Watson SA; Lophatanon A; Muir KA; Guo DA; Bates TE
    Biochem Biophys Res Commun; 2007 Mar; 354(1):50-5. PubMed ID: 17214968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic potential of TRPV1 antagonists.
    Kym PR; Kort ME; Hutchins CW
    Biochem Pharmacol; 2009 Aug; 78(3):211-6. PubMed ID: 19481638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
    Liao C; Liu Y; Liu C; Zhou J; Li H; Wang N; Li J; Liu T; Ghaleb H; Huang W; Qian H
    Bioorg Med Chem; 2018 Feb; 26(4):845-854. PubMed ID: 29317149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
    Gomtsyan A; Bayburt EK; Keddy R; Turner SC; Jinkerson TK; Didomenico S; Perner RJ; Koenig JR; Drizin I; McDonald HA; Surowy CS; Honore P; Mikusa J; Marsh KC; Wetter JM; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3894-9. PubMed ID: 17507218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological and behavioral evidence of a capsaicin-sensitive TRPV-like channel in the medicinal leech.
    Summers T; Holec S; Burrell BD
    J Exp Biol; 2014 Dec; 217(Pt 23):4167-73. PubMed ID: 25324339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
    Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of carbamide derivatives bearing tetrahydroisoquinoline moieties and biological evaluation as analgesia drugs in mice.
    Qiu Q; Wang J; Deng X; Qian H; Lin H; Huang W
    Arch Pharm (Weinheim); 2015 May; 348(5):347-52. PubMed ID: 25824579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic potential of TRPV3 antagonists.
    Reilly RM; Kym PR
    Curr Top Med Chem; 2011; 11(17):2210-5. PubMed ID: 21671874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
    Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
    J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain.
    Chen Y; Yang C; Wang ZJ
    Neuroscience; 2011 Oct; 193():440-51. PubMed ID: 21763756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.